Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DarioHealth Corp. (NASDAQ: DRIO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures made under the Securities Exchange Act of 1934, including Form 8-K current reports and other key documents. These filings provide detailed information on DarioHealth’s capital structure, financing transactions, governance decisions and material agreements, complementing its profile as a digital health company offering a multi-chronic condition digital therapeutics platform for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent Form 8-K filings describe several significant corporate actions. One filing outlines a twenty-for-one reverse stock split of DarioHealth’s common stock, including the effective date, treatment of fractional shares and the impact on outstanding shares and equity-linked instruments. Other 8-Ks report private placements of common stock and pre-funded warrants, including purchase agreements, pricing, exemptions from registration and commitments to file registration statements for resale of the securities.
DarioHealth’s SEC reports also detail amendments to certificates of designation for various series of preferred stock, accelerating mandatory conversion of these preferred shares into common stock or, at holders’ election, pre-funded warrants. Additional filings describe an amendment to the company’s credit agreement, including resets of financial covenants, liquidity requirements, reporting obligations and warrant amendments associated with the loan facility. These documents help investors understand how DarioHealth manages its debt obligations and equity capitalization.
Another Form 8-K explains that the Board of Directors initiated a comprehensive strategic review after receiving multiple unsolicited inbound strategic inquiries, forming a special committee of independent directors and engaging Perella Weinberg Partners as financial advisor. Filings also cover shareholder votes on matters such as equity compensation plans, reverse stock split authorization and increases in authorized shares, as well as executive appointments.
On Stock Titan, DarioHealth’s filings are updated as they are posted to EDGAR, and AI-powered summaries can help interpret complex items such as reverse stock split mechanics, preferred stock conversions, credit agreement amendments and unregistered equity offerings. Users can also review insider and equity-related disclosures reported on Forms 4 and other filings where available, gaining a structured view of DarioHealth’s regulatory and capital markets activity over time.
DarioHealth Corp. completed a private securities offering to accredited investors, selling 1,154,420 shares of common stock and pre-funded warrants to purchase up to 1,558,760 additional common shares at a purchase price of $6.45 per share or pre-funded warrant. The securities were issued in a transaction exempt from SEC registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
The company agreed to file a registration statement for the shares and the pre-funded warrant shares within 30 days after closing. Separately, DarioHealth amended and restated the certificate of designation for its Series C-1 preferred stock to accelerate mandatory conversion of all outstanding shares of that series into common stock, or at each holder’s election into pre-funded warrants, with holders also receiving accrued and unpaid dividends, subject to beneficial ownership blockers.
DarioHealth also announced that its board has begun a comprehensive strategic review to maximize shareholder value after receiving multiple unsolicited strategic inquiries. A special committee of independent directors was formed, and Perella Weinberg Partners was engaged as financial advisor to evaluate options including a sale, merger, strategic business combination, or continued standalone strategy.
DarioHealth Corp. (DRIO) filed an Form 8-K reporting amendments to multiple certificates of designation for its preferred stock series. The filing lists amended or restated certificates for Series A-1, C, C-2, D, D-1, D-2, and D-3 preferred shares and includes an interactive data cover page. The document also references written and soliciting communications under SEC Rules 425, 14a-12, 14d-2(b), and 13e-4(c). The filing is dated September 18–19, 2025 and notes the company’s common stock trades on NASDAQ Capital Market. The filing text lists exhibits but does not disclose the economic or governance terms of the amended designations within the provided excerpt.
Steven Nelson, President and CCO of DarioHealth Corp. (DRIO), reported a non-derivative acquisition on 09/11/2025 of 30,000 restricted shares granted at $0. The award vests on the last day of the second-year anniversary after the grant date. Following the transaction and a 20-for-1 reverse stock split effected on August 28, 2025, Nelson beneficially owns 34,750 shares. The Form 4 was signed on 09/15/2025.
Adam K. Stern, a director of DarioHealth Corp. (DRIO), reported a restricted stock award of 20,000 shares granted on 09/11/2025 at a $0 price. The award is scheduled to vest on the last day of the second-year anniversary after the grant date. Following the reported transaction and reflecting a 20-for-1 reverse stock split effected on August 28, 2025, the filing shows 29,717 shares beneficially owned directly and 6,146 shares beneficially owned indirectly through AKS Family Partners L.P. The filing also discloses indirect beneficial ownership of 123,763 Series-C preferred shares. The form is signed by Mr. Stern on 09/15/2025.
Lawrence B. Leisure, a director of DarioHealth Corp. (DRIO), reported the acquisition of 20,000 shares of common stock as a restricted share award on 09/11/2025. The award is recorded at a price of $0 and will vest on the last day of the two-year anniversary after the grant date, so the shares are not immediately transferable. Following the reporting adjustments for a 20-for-1 reverse stock split effective August 28, 2025, the filing lists 12,900 shares as beneficially owned indirectly through NearWater Growth, LLC. The Form 4 was signed by the reporting person on 09/15/2025.
DarioHealth Corp. (DRIO) director Yoav Shaked reported a restricted share award granted and recorded on 09/11/2025. The filing shows an acquisition of 20,000 shares of common stock at a reported price of $0, structured to vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period. After accounting for a 20-for-1 reverse stock split effected on August 28, 2025, the number of shares beneficially owned by Mr. Shaked is shown as 32,810.
The report also discloses indirect ownership of 84 shares held by the reporting person’s spouse, with the reporting person disclaiming beneficial ownership of those shares. The form is signed by Yoav Shaked on 09/15/2025.
Raphael Erez, who is listed as Chief Executive Officer and a director of DarioHealth Corp. (DRIO), reported a non‑derivative award on this Form 4. On 09/11/2025 he was granted 60,000 restricted shares at a stated price of $0; the award vests in two equal installments on the last day of each successive annual anniversary over a two‑year period. Following the grant and reflecting a 20‑for‑1 reverse stock split effected August 28, 2025, the filing reports total beneficial ownership of 156,853 common shares. The filing also discloses indirect ownership of 1,894 shares through Dicilyon Consulting and Investment Ltd. The report is signed by Mr. Erez on 09/15/2025.
DarioHealth Corp. insider transaction summary The reporting person, Dennis M. McGrath, a company director, received a restricted share award of 20,000 shares of DarioHealth common stock on 09/11/2025 that vests on the last day of the second anniversary of the grant date. Following the award and a prior corporate action, Mr. McGrath is shown as beneficially owning 27,737 shares, an amount that reflects a 20-for-1 reverse stock split effected on 08/28/2025. The transaction is recorded as an acquisition with a reported price of $0 for the restricted shares.
DarioHealth Corp. director Dennis Matheis reported a non‑derivative acquisition of company stock. On 09/11/2025 Mr. Matheis received a restricted share award of 20,000 shares at a reported price of $0. The award is scheduled to vest on the last day of the second anniversary after the grant date. Following the reported transaction, Mr. Matheis beneficially owned 27,631 shares, an amount that reflects a 20‑for‑1 reverse stock split effected on August 28, 2025. The Form 4 was signed on 09/15/2025.
Steven Nelson, President and CCO of DarioHealth Corp. (DRIO), reported an open-market purchase of common stock on 08/27/2025. The Form 4 shows a purchase of 40,000 shares at $0.53 per share, bringing his reported beneficial ownership to 95,000 shares. The filing identifies Nelson as a director and officer and is signed by him on 08/27/2025.